Hexarelin is a GH-releasing peptide investigated in small human experiments. A measurable endocrine response is different from proven strength or long-term health benefit.
What did the cited trial find?
A placebo-controlled 1994 experiment in 12 men observed a temporary GH increase followed by decline during follow-up. It describes short-term endocrine responsiveness. Reference: Hexarelin human GH-response study (1994)
Does it establish strength benefits?
Not directly. Strength, muscle growth and training recovery were not the outcomes this experiment was designed to assess. Those claims need matching studies.
What makes comparisons useful?
Compare populations, follow-up and equivalent outcomes before ranking Hexarelin against other secretagogues. A higher hormone measurement alone does not establish better health.
Frequently asked questions
Has Hexarelin been studied in humans?
Yes. This example is a small short-term GH-response experiment.
Does a larger GH rise always mean better results?
No. Relevant benefit and adverse-outcome data are required.
How should this article be used?
Use it to identify the substance, understand what the cited research measured, and prepare questions for a qualified clinician. It is educational information, not an individual treatment plan.